Blood filter aims to pull toxins from septic shock patients
NCT ID NCT03901807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a device called the PMX cartridge, which filters endotoxins from the blood, can improve survival in people with septic shock. About 150 adults with severe infections and low blood pressure will receive either standard care alone or standard care plus the PMX cartridge. The main goal is to see if the device reduces deaths within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toraymyxin PMX 20R extracorporeal hemoperfusion cartridge (a blood-filtering device that removes endotoxin)
What this could lead to
If it works, this could provide a new treatment option to reduce early death in septic shock patients with endotoxemia.
What could go wrong
This is a mid-stage trial with only 150 participants, so results may not apply to all septic shock patients. The device is invasive and carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baystate Medical Center
Springfield, Massachusetts, 01199, United States
-
CHI Memorial
Chattanooga, Tennessee, 37404, United States
-
Cooper Health System
Camden, New Jersey, 08103, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
George Washington University
Washington D.C., District of Columbia, 20037, United States
-
Institute for Extracorporeal Life Support
San Antonio, Texas, 78229, United States
-
Louisiana State University Health Shreveport
Shreveport, Louisiana, 71103, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Mt Sinai Hospital
New York, New York, 10029, United States
-
Parkridge Hospital
Chattanooga, Tennessee, 37404, United States
-
Pulmonary Associates
Boulder, Colorado, 80909, United States
-
Rutgers, The State University of New Jersey
Piscataway, New Jersey, 08854, United States
-
Stony Brook University
Stony Brook, New York, 11794, United States
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294-0111, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States